Galapagos NV is a Belgium-based biotechnology company focused on developing therapeutics in oncology and immunology, with primary operations in the United States and Europe. The company's pipeline consists of several cell therapy candidates, primarily CAR-T (chimeric antigen receptor T-cell) products designed for point-of-care manufacturing. Its lead programs include GLPG5101 and GLPG5201, both CD19-targeted CAR-T therapies in Phase 1/2 trials for hematologic malignancies, and GLPG5301, a BCMA-targeted CAR-T candidate in Phase 1/2 development for multiple myeloma. Additionally, GLPG3667 has completed Phase 1b evaluation.
The company maintains strategic collaboration agreements with major pharmaceutical partners Gilead Sciences and AbbVie to support its clinical development and commercialization efforts. Galapagos was incorporated in 1999 and operates primarily as a clinical-stage biopharmaceutical developer without significant commercial revenue streams at this time. The company's business model centers on advancing its proprietary CAR-T pipeline through clinical trials, with the point-of-care manufacturing approach representing its technical differentiation in the cell therapy space.
No 10-K filings found.